Bitcoin pioneer Charlie Shrem peels back the layers on the lives and backgrounds of the world's most impactful innovators. Centering around intimate narratives, Shrem uncovers a detailed, previously unspoken story of the genesis and evolution of bitcoin, cryptocurrency, artificial intelligence, and the web3 movements. Join Shrem as he journeys through the uncharted territories of tech revolutions, revealing the human side of the stories that shaped the digital world we live in today.
…
continue reading
Contenuto fornito da CNBC. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da CNBC o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
Player FM - App Podcast
Vai offline con l'app Player FM !
Vai offline con l'app Player FM !
CNBC SPECIAL: Ozempic Underworld 10/11/24
Manage episode 444678012 series 1772318
Contenuto fornito da CNBC. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da CNBC o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
A CNBC investigation into counterfeit weight loss drugs revealed an international illegal marketplace where criminals either brazenly alter the drugs or ship the real product from overseas — what’s known as drug diversion and against federal law. The operations mainly involve phony or illegal versions of Novo Nordisk’s diabetes drug Ozempic and its obesity drug Wegovy as well as Eli Lilly’s Mounjaro and Zepbound. All four drugs are in a class of wildly popular weight loss drugs known as GLP-1s. The skyrocketing demand for the treatments has led to criminal schemes attempting to capitalize on the surge. To view the documentary and read the full article go to https://cnb.cx/3NfQO8V
…
continue reading
1795 episodi
Manage episode 444678012 series 1772318
Contenuto fornito da CNBC. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da CNBC o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
A CNBC investigation into counterfeit weight loss drugs revealed an international illegal marketplace where criminals either brazenly alter the drugs or ship the real product from overseas — what’s known as drug diversion and against federal law. The operations mainly involve phony or illegal versions of Novo Nordisk’s diabetes drug Ozempic and its obesity drug Wegovy as well as Eli Lilly’s Mounjaro and Zepbound. All four drugs are in a class of wildly popular weight loss drugs known as GLP-1s. The skyrocketing demand for the treatments has led to criminal schemes attempting to capitalize on the surge. To view the documentary and read the full article go to https://cnb.cx/3NfQO8V
…
continue reading
1795 episodi
Tutti gli episodi
×Benvenuto su Player FM!
Player FM ricerca sul web podcast di alta qualità che tu possa goderti adesso. È la migliore app di podcast e funziona su Android, iPhone e web. Registrati per sincronizzare le iscrizioni su tutti i tuoi dispositivi.